Bone Marrow Stem Cell Transplant & Congestive Heart Failure (CHF)

Congestive heart failure (CHF) is a serious andautologous stem cell transplantation in the
life-threatening illness that is associated withtreatment of CHF, and may represent a major
premature death. If one thinks of the heart as aadvancement towards finding an enduring
pump, progressive damage to this pump's muscletreatment, if not an eventual cure, for this
fibers results in decreased "pump efficiency,"increasingly common and disabling disease.
which causes blood to, essentially, back-up withinIn this prospective interventional clinical study, 124
the vascular system under increased pressure.patients who had just experienced an acute
This increased back-pressure causes swelling ofmyocardial infarction were evaluated with
the entire body (edema), and particularly thecoronary angiograms, treadmill EKGs, 24-hour
lower extremities, the lungs, the liver, as well asEKGs, and echocardiograms, among other cardiac
within the heart itself. In more severe cases, CHFstudies. Half of this cohort of patient volunteers
is associated with generalized weakness andalso underwent collection of their own
profound shortness of breath.(autologous) bone marrow cells, and injection of
The American Heart Association estimates thatthese bone marrow cells into the blocked
there are already more than 5 million Americanscoronary arteries that had caused these patients'
living with CHF, and that more than 550,000 newheart attacks. Both groups of patients were
cases of CHF are diagnosed each year. Althoughmatched with each other in terms of baseline
mortality rates associated with CHF havecardiac function and the extent of their
improved dramatically over the past 30 years,myocardial infarctions. All 124 patients were then
the 5-year death rate associated with clinicallyclosely followed, at regular intervals, for 5 years.
significant CHF still approaches 50 percent.The results of this study were rather dramatic.
As our population continues to grow older, onWithin 3 months of bone marrow cell injection,
average, the incidence of CHF is expected tosignificant improvement was noted in cardiac
continue to rise. Although precise estimates arepumping efficiency (ejection fraction) of the bone
difficult to arrive at, the cost of caring for CHF ismarrow cell transplant patients, when compared
thought to be at least $33 billion per year in theto the patients who did not receive autologous
United States alone.intracardiac bone marrow cell transfusions.
There are several known major risk factors forMoreover, on average, the total area of heart
CHF, including coronary artery disease and heartmuscle death (infarction) following heart attack
attack (myocardial infarction), uncontrolled highwas 8 percent smaller in the patients who
blood pressure (hypertension), diabetes, obesity,received the bone marrow cell transplants, when
diseased heart valves, elevated cholesterol, andcompared to the "control group" patients.
smoking. In most countries, coronary arteryIn the area of the "infarction zone" of the heart, a
disease and myocardial infarction are the leadingvery significant 31 percent increase in cardiac
causes of CHF, and these two related risk factorscontractility was observed in the patients who had
account for approximately two-thirds of all CHFundergone bone marrow cell transplant, suggesting
cases in the United States.that the infused bone marrow stem cells had
In adults, heart muscle fibers (cardiac myocytes)actually incorporated themselves into the infarcted
that have become damaged by chronic oxygenheart muscle, and had successfully transformed
deprivation (myocardial ischemia) or oxygen lossthemselves into functional cardiac myocytes.
(myocardial infarction) are essentially unable toWhen compared to the control group patients,
regenerate themselves, and are gradually replacedthe patients who had undergone autologous
by scar tissue that interferes with the heart'sintracardiac bone marrow cell transplantation also
pumping action. At the present time, the standardexperienced significantly improved exercise
clinical management of heart injury due totolerance and a decreased risk of death
ischemia or infarction includes the use ofthroughout the 5-year observation period within
medications such as aspirin, ACE inhibitors,this study. Furthermore, these highly significant
aldosterone antagonists, beta-blockers andimprovements in cardiac function continued to
nitrates. So-called "reperfusion strategies," includingremain stable and durable throughout the 5-year
coronary artery stent placement and coronaryperiod of post-transplant observation of these
artery bypass graft (CABG) surgery may also bepatients. As the "treatment group" patients were
required in some patients. However, once theinfused with their own bone marrow cells, there
heart's blood-pumping muscle fibers have becomewere no episodes of rejection, and no major
extensively replaced with non-contractile scarcomplications were reported with this novel
tissue (fibrosis), irreversible CHF develops, andtreatment.
only symptomatic management is possible at thisThis small prospective pilot study strongly
point.suggests that autotransplantation with stem cells
Recent animal studies, and limited clinical researchcontained in the bone marrow can significantly
studies in humans, have looked at the use ofreduce the risk and extent of CHF following acute
stem cell auto-transplantation into damaged heartsmyocardial infarction. Not only does this therapy
afflicted with CHF. Although mature cardiacappear to be clinically effective, but it appears to
myocytes cannot regenerate or reproducebe associated with a very low risk of
following severe ischemia or infarction, primitivecomplications, and it also side-steps the ongoing
"pluropotential" stem cells in the bone marrow areethical debate that surrounds the use of more
thought to be potentially capable, under certainversatile, but more controversial, fetal stem cells.
conditions, of metamorphosing, or differentiating,Based upon the rather remarkable findings of this
themselves into almost any type of specialized cellsmall clinical study, much larger multi-institution,
of the body, including cardiac myocytes. However,prospective, randomized, controlled studies of
this transformation, from undifferentiated boneautologous intracardiac bone marrow cell
marrow stem cell into a highly differentiated andtransplantation, following acute myocardial
specialized cardiac muscle cell, does not occurinfarction, need to be performed. Fortunately,
naturally in the human body, at least not to anyseveral such studies are already underway in the
clinically significant degree. Therefore, as is alsoUnited States and Europe. I look forward to the
the case in other areas of stem cell research, thelong-term results of such studies, as I believe that
greatest challenge in this type of clinical researchthey may have the potential to radically
is in coaxing undifferentiated stem cells to morphtransform the management of coronary artery
into functional cardiac myocytes and to find adisease and acute myocardial infarction, and offer
way to incorporate these new heart muscle cellsthe best and most practical hope of reducing both
into the damaged heart in such a way that theythe incidence of CHF and the mortality rate
actually improve the damaged heart'sassociated with CHF.
compromised pumping function. (These twoThe information in this column is intended for
challenges continue to vex clinical research intoinformational purposes only, and does not
stem cell therapy, and particularly research intoconstitute medical advice or recommendations by
the use of adult patients' own stem cells.)the author. Please consult with your physician
Now, newly published clinical research in the Journalbefore making any lifestyle or medication
of the American College of Cardiology appears tochanges, or if you have any other concerns
have pushed the existing boundaries of so-calledregarding your health.